Extracellular matrix in deoxycholic acid decellularized aortic heart valves

Medical Science Monitor

Volumn 18, Issue 12, 2012, Pages

  Bloch, Oliver ^a   Erdbrügger, Wilhelm ^b   Völker, Wolfgang ^c   Schenk, Alexander ^b   Posner, Steffen ^b   Konertz, Wolfgang ^a   Dohmen, Pascal M ^d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b AutoTissue Ltd   (Germany)

^c Leibniz Institute for Arteriosclerosis Research   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Aortic valve; Bioengineering; In vitro studies; Replacement; Tissue engineering; Xenograft

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHONDROITIN ABC LYASE; DEOXYCHOLIC ACID; GLYCOSAMINOGLYCAN; PROTEOGLYCAN;

ANIMAL TISSUE; AORTA VALVE; ARTICLE; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOLYSIS; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HISTOCHEMISTRY; NONHUMAN; OPTICAL DENSITY; PHOTOMETRY; PROTEIN ANALYSIS; PROTEIN DEPLETION; SWINE;

ANIMALS; AORTIC VALVE; DEOXYCHOLIC ACID; EXTRACELLULAR MATRIX; INDOLES; ORGANOMETALLIC COMPOUNDS; STAINING AND LABELING; SUS SCROFA;

EID: 84874776381     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883618     Document Type: Article

References (31)

1. Erdbrügger W, Konertz W, Dohmen PM et al: Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng, 2006; 12: 2059-68
2. Konertz W, Dohmen PM, Liu J et al: Hemodynamic characteristics of the Matrix P decellularized xenograft for pulmonary valve replacement during the Ross operation. J Heart Valve Dis, 2005; 14: 78-81
3. Bechtel JF, Stierle U, Sievers HH: Fifty-two months' mean follow up of decellularized SynerGraft-treated pulmonary valve allografts. J Heart Valve Dis, 2008; 17: 98-104
4. Dohmen PM, Lembcke A, Hotz H et al: Ross operation with a tissueengineered heart valve. Ann Thorac Surg, 2002; 79: 1438-42
5. da Costa F, Costa A, Prestes R et al: The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg, 2010; 90: 1854-60
6. Simon P, Kasimir MT, Seebacher G et al: Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg, 2003; 23: 1002-6
7. Dohmen PM, da Costa F, Holinski S et al: Is there a possibility for a glutaraldehyde-free porcine heart valve to grow? Eur Surg Res, 2006; 38: 54-61
8. Dohmen PM, Lembcke A, Holinski S et al: Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann Thorac Surg, 2007; 84: 729-36
9. Dohmen PM, Lembcke A, Holinski S et al: Ten years of clinical results with a tissue-engineered pulmonary valve. Ann Thorac Surg, 2011; 92: 1308-14
10. Dohmen PM, Hauptmann S, Terytze A, Konertz W: In-vivo repopularization of a tissue-engineered heart valve in a human subject. J Heart Valve Dis, 2007; 16: 447-49
11. Bloch O, Golde P, Dohmen PM et al: Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves. Tissue Eng Part A, 2011; 17: 2399-405
12. Iwamoto R, Mine N, Kawaguchi T et al: HB-EGF function in cardiac valve development requires interaction with heparan sulfate proteoglycans. Development, 2010; 137: 2205-14
13. Grande-Allen KJ, Calabro A, Gupta V et al: Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordate: association with regions of tensile and compressive loading. Glycobiology, 2004; 14: 621-33
14. Stephens EH, Chu C-K, Grande-Allen KJ: Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechincal load and age: Relevance to an age-specific tissue-engineenered heart valve. Acta Biomaterialia, 2008; 4: 1148-60
15. Völker W, Schmidt A, Buddecke E: Compartmentation and characterizaton fo different proteoglycans in bovine arterial wall. J. Histochem. Cytochem, 1986; 34: 1293-99
16. Scott JE: Morphometry of cupromeronic blue-stained proteoglycan molecules in animal corneas, versus that of purified proteoglycans stained in vitro, implies that tertiary structures contribute to corneal ultrastructure. J Anat, 1992; 180: 155-64
17. Völker W, Strazynski M, Rothenburger M, Vischer P: Engineering of vascular tissue with a structurally organized extracellular matrix. In: Sames K, Sethe S, Stolzing A (eds.) Extending the Lifespan-Biotechnical, Gerontological, and Social Problems. LIT Verlag Münster, Germany, ISBN 3-8258-8563-1. 205-216 (2005)
18. Rothenburger M, Völker W, Vischer P et al: Ultrastructure of proteoglycans in tissue-engineered cardiovascular structures. Tissue Eng, 2002; 8: 1049-56
19. Rothenburger M, Völker W, Vischer P et al: Tissue engineering of heart valves: formation of a three-dimensional tissue using porcine heart valve cells. ASAIO J, 2002; 48: 586-91
20. Seligman AM, Wasserkrug HL, Hanker JS: A new staining method (OTO) for enhancing contrast of lipid-containing membranes and dropletes in osmium tetroxide-fixed tissue with osmiophilic thiocarbohydrazide (TCH). J Cell Biol, 1966; 30: 424-32
21. Stephens EH, Chu CK, Grande-Allen KJ: Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve. Acta Biomater, 2008; 4: 1148-60
22. Chen JH, Simmons CA: Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res, 2011; 108: 1510-24
23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72: 248-54
24. Farndale RW, Buttle DJ, Barrett AJ: Impoved quantification and discrimination of sulphated glycosaminoglycans by use of dimethylmethylen blue. Biochim Biophys Acta, 1986; 833: 173-77
25. Grande-Allen KJ, Mako WJ, Calabro A et al: Loss of chondroitin 6-sulfate and hyaluronan from failed porcine bioprosthetic valves. J Biomed Mater Res A, 2003; 65: 2519
26. Arai S, Orton EC. Immunoblot detection of soluble protein antigens from sodium dodecyl sulfate-and sodium deoxycholate-treated candidate bioscaffold tissues. J Heart Valve Dis, 2009; 18: 439-43
27. Kasimir MT, Rieder E, Seebacher G et al: Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs, 2003; 26: 421-27
28. Schenke-Layland K, Vasilevski O, Opitz F et al: Impact of decellularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves. J Struct Biol, 2003; 143: 201-8
29. Zhou J, Fritze O, Schleicher M et al: Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials, 2010; 31: 2549-54
30. Bastian F, Stelzmüller ME, Kratochwill K et al: IgG deposition and activation of the classical complement pathway involvement in the activation of human granulocytes by decellularized porcine heart valve tissue. Biomaterials, 2008; 29: 1824-32
31. Tudorache I, Cebotari S, Sturz G et al: Tissue engineering of heart valves: biomechanical andmorphological properties of decellularized heart valves. J Heart Valve Dis, 2007; 16: 567-73